Melanocyte-Stimulating Hormone Release-Inhibiting Factor (trifluoroacetate salt)
(Synonyms: MIF-1, MSH-R-IF) 目录号 : GC45509A tripeptide with diverse biological activities
Sample solution is provided at 25 µL, 10mM.
Melanocyte-stimulating hormone release-inhibiting factor (MSH-R-IF) is a hypothalamic tripeptide that binds to rat striatum (Kd = 4.69 nM) and has diverse biological activities.1,2,3,4 In vivo, MSH-R-IF (0.1 mg/kg) decreases immobility of mice in the forced swim test, indicating antidepressant-like activity.2 MSH-R-IF (20 mg/kg) increases striatal concentration of dopamine and the dopamine metabolites DOPAC, 3-methoxy tyramine , and homovanillic acid (HVA) in a mouse model of Parkinson's disease induced by MPTP.3 It decreases vacuous chewing movements induced by haloperidol in a rat model of tardive dyskinesia when administered at a dose of 2 mg/kg.4 MSH-R-IF also has anti-opiate effects, reversing analgesia induced by morphine and an enkephalin in mice in a radiant heat tail-flick assay.1
References
1. Pan, W., and Kastin, A.J. From MIF-1 to endomorphin: The Tyr-MIF-1 family of peptides. Peptides 28(12), 2411-2434 (2007).
2. Kastin, A.J., Abel, D.A., Ehrensing, R.H., et al. Tyr-MIF-1 and MIF-1 are active in the water wheel test for antidepressant drugs. Pharmacol. Biochem. Behav. 21(5), 767-771 (1984).
3. Marcotte, E.R., Chugh, A., Mishra, R.K., et al. Protection against MPTP treatment by an analog of Pro-Leu-Gly-NH2 (PLG, MIF-1). Peptides 19(2), 403-406 (1998).
4. Sharma, S., Paladino, P., Gabriele, J., et al. Pro-Leu-glycinamide and its peptidomimetic, PAOPA, attenuate haloperidol induced vacuous chewing movements in rat: A model of human tardive dyskinesia. Peptides 24(2), 313-319 (2003).
Cas No. | SDF | ||
别名 | MIF-1, MSH-R-IF | ||
Canonical SMILES | O=C([C@@H](NC([C@H]1NCCC1)=O)CC(C)C)NCC(N)=O.FC(F)(C(O)=O)F | ||
分子式 | C13H24N4O3.XCF3COOH | 分子量 | 284.4 |
溶解度 | Water: 1 mg/ml | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 3.5162 mL | 17.5809 mL | 35.1617 mL |
5 mM | 0.7032 mL | 3.5162 mL | 7.0323 mL |
10 mM | 0.3516 mL | 1.7581 mL | 3.5162 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet